Literature DB >> 30103868

Modifying the physicochemical properties of NSAIDs for nasal and pulmonary administration.

P Szabó-Révész1.   

Abstract

This review focuses on nasal and pulmonary delivery of NSAIDs (non-steroidal anti-inflammatory drugs) for fast-onset analgesia, for the potential prevention of Alzheimer's disease (AD), as well as for an add-on treatment in cystic fibrosis (CF) and non-small cell lung cancer (NSCLC). I discuss how the physicochemical properties of NSAIDs can be modified with respect to the biological characteristics of the target site. Innovative technology and/or dosage forms can promote an effective therapy.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30103868     DOI： 10.1016/j.ddtec.2018.03.002

Source DB:  PubMed          Journal:  Drug Discov Today Technol        ISSN： 1740-6749


  7 in total

1.  Transformation of Meloxicam Containing Nanosuspension into Surfactant-Free Solid Compositions to Increase the Product Stability and Drug Bioavailability for Rapid Analgesia.

Authors:  Csaba Bartos; Rita Ambrus; Gábor Katona; Tamás Sovány; Róbert Gáspár; Árpád Márki; Eszter Ducza; Anita Ivanov; Ferenc Tömösi; Tamás Janáky; Piroska Szabó-Révész
Journal:  Drug Des Devel Ther       Date:  2019-11-28       Impact factor: 4.162

2.  Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach.

Authors:  Gábor Katona; György Tibor Balogh; Gergő Dargó; Róbert Gáspár; Árpád Márki; Eszter Ducza; Anita Sztojkov-Ivanov; Ferenc Tömösi; Gábor Kecskeméti; Tamás Janáky; Tamás Kiss; Rita Ambrus; Edina Pallagi; Piroska Szabó-Révész; Ildikó Csóka
Journal:  Pharmaceutics       Date:  2020-01-25       Impact factor: 6.321

3.  Quality by Design Based Formulation Study of Meloxicam-Loaded Polymeric Micelles for Intranasal Administration.

Authors:  Bence Sipos; Piroska Szabó-Révész; Ildikó Csóka; Edina Pallagi; Dorina Gabriella Dobó; Péter Bélteky; Zoltán Kónya; Ágota Deák; László Janovák; Gábor Katona
Journal:  Pharmaceutics       Date:  2020-07-24       Impact factor: 6.321

4.  Formulation and In Vitro and In Silico Characterization of "Nano-in-Micro" Dry Powder Inhalers Containing Meloxicam.

Authors:  Petra Party; Csilla Bartos; Árpád Farkas; Piroska Szabó-Révész; Rita Ambrus
Journal:  Pharmaceutics       Date:  2021-02-03       Impact factor: 6.321

5.  Development of In Situ Gelling Meloxicam-Human Serum Albumin Nanoparticle Formulation for Nose-to-Brain Application.

Authors:  Gábor Katona; Bence Sipos; Mária Budai-Szűcs; György Tibor Balogh; Szilvia Veszelka; Ilona Gróf; Mária A Deli; Balázs Volk; Piroska Szabó-Révész; Ildikó Csóka
Journal:  Pharmaceutics       Date:  2021-05-01       Impact factor: 6.321

6.  Development of an Innovative, Carrier-Based Dry Powder Inhalation Formulation Containing Spray-Dried Meloxicam Potassium to Improve the In Vitro and In Silico Aerodynamic Properties.

Authors:  Edit Benke; Árpád Farkas; Piroska Szabó-Révész; Rita Ambrus
Journal:  Pharmaceutics       Date:  2020-06-10       Impact factor: 6.321

7.  Application of pulsed laser ablation (PLA) for the size reduction of non-steroidal anti-inflammatory drugs (NSAIDs).

Authors:  Tamás Gera; Eszter Nagy; Tamás Smausz; Judit Budai; Tibor Ajtai; Fruzsina Kun-Szabó; Zsolt Homik; Judit Kopniczky; Zoltán Bozóki; Piroska Szabó-Révész; Rita Ambrus; Béla Hopp
Journal:  Sci Rep       Date:  2020-09-25       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.